Boston Scientific touts 65% efficacy for Farapulse PFA in persistent AF trial
Boston Scientific shared the results during a late-breaking presentation at this year’s EHRA congress in Paris, France.
Featured s
ProSomnus secures FDA clearance for RPMO2 device
RPMO₂ features a fully embedded oximeter over maxillary dentition, using buccal vestibule mucosa behind the upper lip.
All Articles
Boston Scientific touts 65% efficacy for Farapulse PFA in persistent AF trial
Boston Scientific shared the results during a late-breaking presentation at this year’s EHRA congress in Paris, France.
ProSomnus secures FDA clearance for RPMO2 device
RPMO₂ features a fully embedded oximeter over maxillary dentition, using buccal vestibule mucosa behind the upper lip.
Heartflow sues Cleerly over patent infringement allegations
Heartflow alleges that after working as its consultant, Cleerly’s CEO launched a competing enterprise “built upon” Heartflow’s innovations.
J&J reports 12-month data for Varipulse PFA platform
The complete study cohort includes 1,023 patients from 22 sites in Europe.
Stryker agrees to acquire IVL developer Amplitude Vascular Systems
Amplitude Vascular’s lead development product is an intravascular lithotripsy platform for calcified peripheral artery disease treatment.
Beckman Coulter obtains CE mark for bacterial-viral differentiator test
Used with Beckman’s immunoassay analysers, MeMed’s BV test has been demonstrated to reduce unnecessary antibiotic use.
Roche’s Elecsys NfL test earns CE mark for multiple sclerosis detection
The test operates on the company's cobas instruments, providing standardised results regardless of location.
Zebra Technologies and Aiva Health team up on nurse solutions
Aiva’s AI assistant enables nurses to use natural voice commands for documentation and work order submissions.
Dreem Health joins Amazon’s Health Benefits Connector
The integration with Amazon presents a means for Amazon customers to enrol and gain access to services that are part…
Boehringer hands over $50m and market rights for Click’s digital therapeutic
Click's CT-155 commercialisation plan comes as regulatory-approved digital therapeutics experience strong market growth.
